Tumour heterogeneity and resistance to cancer therapies

By I. Dagogo-Jack, A. Shaw. Nature Reviews Clinical Oncology, 2017

3,251 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a7a954718a92e4edfcf635c173cf989cae048726

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Carlotta Pucci
2. Gianni Ciofani
3. Carlos L. Arteaga
4. C. Martinelli
5. A. Hanker
6. D. Sudhan

In Oncology

1. Carlos L. Arteaga
2. A. Hanker
3. D. Sudhan

In Pulmonary and Respiratory Medicine

1. Carlos L. Arteaga
2. A. Hanker
3. D. Sudhan

Citations in the corpus

• Overcoming Endocrine Resistance in Breast Cancer (2020, positive): “The resulting heterogeneity increases the probability of the presence of clones expressing resistance-promoting transcriptional programs (Dagogo-Jack and Shaw, 2018).”
• Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “This heterogeneity can be appreciated both at spatial and temporal levels and is the key factor responsible for the development of resistant phenotypes promoted by a selective pressure upon treatment administration [1].”
• Large Scale Foundation Model on Single-cell Transcriptomics (2023, neutral): “https://doi.org/10.1038/s41592-024-02305-7 sequenced on an early 10x Chromium platform.”